HACKENSACK, N.J. (November 22, 2010) – The John Theurer Cancer Center at Hackensack University Medical Center announced today that it will present research updates and clinical trial results of 40 cutting-edge studies at the 52nd Annual American Society of Hematology (ASH) Meeting in Orlando from December 4 – 7. The presentations showcased at ASH will include 12 oral sessions and 28 poster presentations, including multicenter, international trials in collaboration with leading cancer institutions, such as the National Cancer Institute, MD Anderson, Dana-Farber, Mayo Clinic, Cleveland Clinic and Memorial Sloan Kettering.
ASH is the world's largest professional society concerned with the causes and treatments of blood disorders. The research presented by the John Theurer Cancer Center will include advancements made in research and clinical trials in lymphoma, multiple myeloma, blood and bone marrow stem cell transplantation, sickle cell, leukemia, and myelodysplastic syndromes.
"We have a long-standing commitment to expand our research capabilities, which includes investing in clinical and research talent, new technology, and infrastructure improvements. As a result, we are presenting twice as many studies compared to last year at this premier hematology conference," said Andre Goy, M.D., M.S., deputy director, director of clinical and translational research, and chief of lymphoma of the John Theurer Cancer Center. "Furthermore, six investigators were first authors of 13 studies, including multicenter trials, establishing our leadership role in the fight against cancer."
In January 2011, the John Theurer Cancer Center will begin treating patients in a new building that will allow the cancer center to further expand its commitment to research and innovation. Breakthrough advances being pioneered in this new facility will include a dedicated Phase 1 Unit, tumor banking to help development of biomarkers as part of next generation clinical trials, new state-of-the-art radiotherapy systems, and functional imaging.
Lead authors presenting at ASH from the John Theurer Cancer Center include Dr. Goy; David Siegel, M.D. , co-chief, multiple myeloma; David Vesole, M.D., co-chief and research director, multiple myeloma; Stuart Goldberg, M.D., chief, leukemia; Anthony R. Mato, M.D., attending, lymphoma; and Jenny Zilberberg, Ph.D., associate, research.
"We are thankful to the hundreds of patients who participated in these clinical trials, which allows us to study some of the most promising cancer-treatment candidates in the pipeline," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., chief innovation officer and professor and vice president of cancer services, the John Theurer Cancer Center. "Their contribution is essential as our researchers and clinicians endeavor to advance treatment and develop new therapies in this fight against cancer."
John Theurer Cancer Center 2010 ASH Abstract Highlights
The following are key abstracts being presented at ASH from the John Theurer Cancer Center. For a complete list of the 40 abstracts and ongoing updates, please visit jtcancercenter.org/ash2010.
Blood and Marrow Stem Cell Transplantation
Multiple Myeloma
Lymphoma
Leukemia
Personalized Medicine and Hematologic Malignancies
For full-text abstracts and more information about the ASH annual meeting, please visit hematology.org/Meetings/Annual-Meeting .
About the John Theurer Cancer Center at Hackensack University Medical Center
The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of after care services that distinguish the John Theurer Cancer Center from other facilities. For more information please go to jtcancercenter.org .